KR20030042020A - 에스트로겐 수용체 조절제 - Google Patents

에스트로겐 수용체 조절제 Download PDF

Info

Publication number
KR20030042020A
KR20030042020A KR10-2003-7005518A KR20037005518A KR20030042020A KR 20030042020 A KR20030042020 A KR 20030042020A KR 20037005518 A KR20037005518 A KR 20037005518A KR 20030042020 A KR20030042020 A KR 20030042020A
Authority
KR
South Korea
Prior art keywords
alkyl
group
compound
ppm
halogen
Prior art date
Application number
KR10-2003-7005518A
Other languages
English (en)
Korean (ko)
Inventor
디닌노프랭크피
쳉헬렌와이
김성곤
위제인와이
Original Assignee
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 앤드 캄파니 인코포레이티드 filed Critical 머크 앤드 캄파니 인코포레이티드
Publication of KR20030042020A publication Critical patent/KR20030042020A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2003-7005518A 2000-10-19 2001-10-15 에스트로겐 수용체 조절제 KR20030042020A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19
US60/241,582 2000-10-19
PCT/US2001/042735 WO2002032377A2 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
KR20030042020A true KR20030042020A (ko) 2003-05-27

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7005518A KR20030042020A (ko) 2000-10-19 2001-10-15 에스트로겐 수용체 조절제

Country Status (20)

Country Link
EP (1) EP1333827A2 (no)
JP (1) JP2004511502A (no)
KR (1) KR20030042020A (no)
CN (1) CN1469743A (no)
AU (2) AU2002232381B2 (no)
BG (1) BG107676A (no)
BR (1) BR0114689A (no)
CA (1) CA2424729A1 (no)
EA (1) EA200300474A1 (no)
EC (1) ECSP034558A (no)
EE (1) EE200300153A (no)
HU (1) HUP0303563A2 (no)
IL (1) IL154984A0 (no)
IS (1) IS6761A (no)
MX (1) MXPA03003485A (no)
NO (1) NO20031737L (no)
PE (1) PE20021083A1 (no)
PL (1) PL361053A1 (no)
SK (1) SK4772003A3 (no)
WO (1) WO2002032377A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
EP1501819B1 (en) 2002-04-24 2010-09-15 Merck Sharp & Dohme Corp. Estrogen receptor modulators
EP1577288B1 (en) * 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Selective estrogen receptor modulators
NZ566180A (en) * 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
JPWO2007049798A1 (ja) * 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
JP5813626B2 (ja) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション 新規抗炎症剤
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
KR102011641B1 (ko) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة

Also Published As

Publication number Publication date
CN1469743A (zh) 2004-01-21
AU3238102A (en) 2002-04-29
HUP0303563A2 (hu) 2004-03-01
BR0114689A (pt) 2003-07-01
ECSP034558A (es) 2003-06-25
PL361053A1 (en) 2004-09-20
PE20021083A1 (es) 2002-12-16
EE200300153A (et) 2003-06-16
BG107676A (bg) 2003-11-28
CA2424729A1 (en) 2002-04-25
IS6761A (is) 2003-03-27
WO2002032377A2 (en) 2002-04-25
MXPA03003485A (es) 2003-07-14
NO20031737L (no) 2003-06-19
EP1333827A2 (en) 2003-08-13
AU2002232381B2 (en) 2004-11-18
NO20031737D0 (no) 2003-04-15
SK4772003A3 (en) 2003-08-05
EA200300474A1 (ru) 2003-10-30
JP2004511502A (ja) 2004-04-15
WO2002032377A3 (en) 2002-08-22
IL154984A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
KR20030042020A (ko) 에스트로겐 수용체 조절제
CA2527203C (en) Casr antagonist
TWI232218B (en) Substituted cyclic amine metalloprotease inhibitors
PT1501819E (pt) Moduladores dos receptores de estrogéneo
JP2010248209A (ja) ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
KR20020067574A (ko) 니트로소화 및 니트로실화된 사이클로옥시게나아제-2억제제, 조성물 및 그 이용방법
CN101180290A (zh) 氢化苯并[c]噻吩衍生物作为免疫调节剂
KR102446027B1 (ko) 함질소 6원환 화합물
UA67790C2 (uk) Бензоциклогептени та лікарський засіб на їх основі
AU2002232381A1 (en) Estrogen receptor modulators
JP3230699B2 (ja) 心臓保護トコフェロ−ル類似体
US6750213B2 (en) Estrogen receptor modulators
WO2004073612A2 (en) Estrogen receptor modulators
JP2004511501A (ja) エストロゲン受容体モジュレーター
BRPI0713743A2 (pt) composto ou um sal do mesmo, pró-droga, e, composição farmacêutica
US20030225132A1 (en) Estrogen receptor modulators
WO2005105823A1 (fr) Derives steroidiens
JP2017513934A5 (no)
US20040044226A1 (en) Estrogen receptor modulators
JPH04316557A (ja) ６−アリール環状アントラニル酸誘導体
WO2004073610A2 (en) Estrogen receptor modulators
KR100302372B1 (ko) 골다공증예방및치료제로서의디히드로에피안드로스테론유도체
JP4176150B2 (ja) グルタミン酸放出阻害剤および新規化合物
JP5662618B2 (ja) 新規システイン化合物及びその塩
CN1411379A (zh) 心律失常的预防剂或药物

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid